Related Experiment Video

Updated: Jun 5, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis

Peng Chen1, Long Wang, Bing Liu

  • 1Department of Stomatology, Chinese People's Liberation Army General Hospital, No.28 Fuxing Road, Haidian District, Beijing, 100853, People's Republic of China.

European Journal of Clinical Pharmacology
|January 6, 2011
PubMed
Abstract

Insights

Cetuximab combined with chemotherapy improves outcomes for advanced non-small-cell lung cancer (NSCLC) patients. Small-molecule tyrosine kinase inhibitors offer marginal benefits when added to chemotherapy for NSCLC.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) is a key target in cancer therapy.
  • The role of EGFR-targeted therapies combined with chemotherapy in advanced non-small-cell lung cancer (NSCLC) requires clarification.

Purpose of the Study:

  • To systematically evaluate the efficacy and safety of EGFR-targeted therapies plus chemotherapy for advanced NSCLC.
  • To compare outcomes of combination therapies versus chemotherapy alone.

Main Methods:

  • Systematic review and quantitative analysis of randomized controlled trials (RCTs).
  • Searches conducted in Cochrane Central Register of Controlled Trials, PubMed, and Embase.
  • Evaluation of survival rates, response, and toxicity.

Main Results:

  • Ten RCTs involving 5,936 patients were analyzed.
  • Cetuximab plus platinum-based doublet chemotherapy (PBDC) showed prolonged overall survival (OS), increased overall response rate (ORR), and 1-year survival (OYS) compared to PBDC alone.
  • Small-molecule tyrosine kinase inhibitors (TKIs) plus PBDC demonstrated marginally improved progression-free survival and ORR, with no significant difference in OS or OYS.

Conclusions:

  • Cetuximab offers significant benefits when added to PBDC for advanced NSCLC.
  • Small-molecule TKIs provide a slight additive efficacy when combined with PBDC in NSCLC treatment.
  • Adverse events were comparable, except for increased rash and diarrhea with combination therapies.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...